Kane Biotech IncOTCQB:KNBIFView on Canadian Exchange
- LAST PRICE0.0770
- TODAY'S CHANGE (%)0.0005 (0.6273%)
- Bid / Lots0.0707/ 100
- Ask / Lots100.0800/ 1
- Open / Previous Close0.0808 / 0.0765
- Day Range
- 52 Week Range
- Volume9,307
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KNBIF |
|---|---|---|
| 12:01 ET | 4000 | 0.077 |
| 02:38 ET | 4000 | 0.077 |
Nov 14, 2024
Kane Biotech Announces Health Canada Approval of revyve(TM) Antimicrobial Wound Gel, from 1:10PM ET on Thursday Nov 14, 2024 by Dow Jones
1:10PM ET on Thursday Nov 14, 2024 by Dow JonesKane Biotech Provides Investor Update Following FB Dermatology Acquisition Announcement, from 8:30AM ET on Thursday Nov 14, 2024 by Dow Jones
8:30AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 12, 2024
Canadian Investment Regulatory Organization Trade Resumption - KNE, from 1:27PM ET on Tuesday Nov 12, 2024 by Dow Jones
1:27PM ET on Tuesday Nov 12, 2024 by Dow JonesKane Biotech Announces Agreement to Acquire FB Dermatology, from 1:08PM ET on Tuesday Nov 12, 2024 by Dow Jones
1:08PM ET on Tuesday Nov 12, 2024 by Dow JonesCanadian Investment Regulatory Organization Trading Halt - KNE, from 1:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
1:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kane Biotech Inc | 13.8M | --- | --- |
Company Information
Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.
Contact Information
- Headquarters
- 290-100 Innovation DriveWINNIPEG, MB, Canada R3T 6G2
- Phone
- 204-453-1301
- Fax
- 204-474-7552
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $13.8M |
|---|---|
Revenue (TTM) | $757.1K |
Shares Outstanding | 131.8M |
Kane Biotech Inc does not pay a dividend. | |
Beta | 0.48 |
EPS | $-0.04 |
Book Value | $-0.08 |
P/E Ratio | --- |
Price/Sales (TTM) | 18.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -597.09% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
